Related Experiment Video
Updated: Jul 23, 2025
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment
Adrian Vasile Dumitru1,2, Dana Antonia Țăpoi1,2, Georgian Halcu1,3
1Department of Pathology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Abstract:
CD30, also known as TNFRSF8 (tumor necrosis factor receptor superfamily member 8), is a protein receptor that is heavily glycosylated inside the Golgi apparatus, as well as a tumor marker that is found on the surface of specific cells in the body, including certain immune cells and cancer ones. This review aims to shed light on the critical importance of CD30, from its emergence in the cell to its position in diagnosing various diseases, including Hodgkin lymphoma, where it is expressed on Hodgkin and Reed-Sternberg cells, as well as embryonal carcinoma, anaplastic large cell lymphoma (ALCL), and cutaneous T-cell lymphoma (CTCL). In addition to its role in positive diagnosis, targeting CD30 has been a promising approach treating CD30-positive lymphomas, and there is ongoing research into the potential use of CD30-targeted therapies for autoimmune disorders. We aim to elaborate on CD30's roles as a tumor marker, supporting thus the hypothesis that this receptor might be the aim of cytostatic treatment.
Insights
CD30 (tumor necrosis factor receptor superfamily member 8) is a crucial tumor marker for diagnosing lymphomas and other cancers. Targeting CD30 offers a promising therapeutic strategy for these diseases and potential autoimmune disorders.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- CD30, also known as TNFRSF8, is a heavily glycosylated protein receptor.
- It functions as a tumor marker found on specific immune and cancer cells.
- CD30 expression is critical in diagnosing various malignancies.
Purpose of the Study:
- To review the multifaceted roles of CD30.
- To highlight its significance in disease diagnosis and therapeutic targeting.
- To explore its potential in treating lymphomas and autoimmune disorders.
Main Methods:
- Literature review of CD30's biological functions.
- Analysis of CD30's role in the diagnosis of specific cancers.
- Examination of CD30-targeted therapies and ongoing research.
Main Results:
- CD30 is expressed on Hodgkin lymphoma, embryonal carcinoma, ALCL, and CTCL cells.
- It serves as a key diagnostic marker for these conditions.
- Targeting CD30 demonstrates therapeutic potential for CD30-positive lymphomas.
Conclusions:
- CD30 is a vital tumor marker with diagnostic and therapeutic implications.
- CD30-targeted therapies are effective for lymphomas and may benefit autoimmune diseases.
- Further research supports CD30 as a target for cytostatic treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...